近五年代表性论文
[1] X Yin#, Q Wang#, M Zhang, C Zhang, Q Chen*, H Li, Y Zhao, Y Wang, J Wang*, L Zhang*, H Cui*. Redox-responsive dual-drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance. Smart Molecules, 2026.
[2] S. Lin#, L. Zhang#, H. Cui, et al. Pharmacokinetics modulation in solid tumors through thrombin-embedded nanomedicine. Journal of Nanobiotechnology, 2025, 23:268. （IF=12.6）
[3] Y. Zhang#, L. Zhang#, H. Gao, et al. Multi-functional lipid nanoformulations for enhancing the efficacy of mRNA tumor vaccines by reversing tumor immunosuppressive microenvironment. Nano Today, 2025, 63:102757. （IF=10.9）
[4] L. Zhang#, J. Wang#, H. Cui, H. Zheng, X. Yin, J. Lin, Y. Wang, Y. Zhao, H. Li g, Q. Chen. Simultaneous knockdown of immune suppressive markers by tumor microenvironment-responsive multifaceted prodrug nanomedicine. ACS Applied Materials & Interfaces, 2023, 15(10), 12864-12881. （IF=8.2）
[5] L. Zhang, H. Zheng, H. Cui, X. et al. Nanomicelle-Based Redox-Responsive Dual-Prodrug for Synergistic Breast Cancer Chemo-Immunotherapy. ACS Applied Nano Materials, 2023, 6, 19, 18263–18274. （IF=5.5）
[6] H. Li#, L. Zhang#, J. Han#, et al. Molecular structural evolution of NIR cationic AIEgens: preclinical antimicrobial pathogens activities and tissues regeneration. CCS Chemistry, 2022, 4, 487-500. （IF=9.2）
[7] L. Zhang, M. Qian, H. Cui, et al. Spatiotemporal concurrent liberation of cytotoxins from dual-prodrug nanomedicine for synergistic antitumor therapy. ACS Applied Materials & Interfaces, 2021.02, 13, 6053–6068. （IF=8.2）
授权专利
[1] ZL202510093662.6，张留伟;陈麒先;张玉峰;林佳奇;崔洪燕，一种逆转肿瘤免疫微环境的多功能纳米制剂及其制备方法和应用
[2] ZL202310403221.2，陈麒先;王静云;崔洪燕;郑浩男;李海东;张留伟 ，一种用于蛋白质递送的多级响应型聚合物囊泡的制备方法
[3] ZL202211567776.2，陈麒先;王静云;郑浩男;崔洪燕;张留伟;李海东，一种能协同化疗逆转肿瘤微环境的JQ1前药纳米粒子及其制备方法和应用
[4] ZL202510139658.9，陈麒先;张宇豪;张留伟，基于变分编码的药物靶标结合性预测方法
[5] ZL202511836248.6，陈麒先;张宇豪;张留伟;崔洪燕，一种基于混合深度学习模型的RNA二级结构预测方法
[6] ZL202111275445.7，王静云;曾爽;陈麒先;张留伟，可激活肿瘤细胞焦亡的细胞器靶向光敏剂及其制备方法和应用
2014.9-2021.12，大连理工大学，生物工程学院，生物化工，博士
2010.9-2014.7，大连民族大学，生命科学学院，生物工程，学士
2023.12-至今，浙江大学长三角智慧绿洲创新中心，未来健康实验室，特聘副研究员
2024.5-至今，浙江大学，药学院，硕士生导师
2021.12-2023.12，大连理工大学，医学部，生物医学工程，博士后
近五年代表性论文
[1] X Yin#, Q Wang#, M Zhang, C Zhang, Q Chen*, H Li, Y Zhao, Y Wang, J Wang*, L Zhang*, H Cui*. Redox-responsive dual-drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance. Smart Molecules, 2026.
[2] S. Lin#, L. Zhang#, H. Cui, et al. Pharmacokinetics modulation in solid tumors through thrombin-embedded nanomedicine. Journal of Nanobiotechnology, 2025, 23:268. （IF=12.6）
[3] Y. Zhang#, L. Zhang#, H. Gao, et al. Multi-functional lipid nanoformulations for enhancing the efficacy of mRNA tumor vaccines by reversing tumor immunosuppressive microenvironment. Nano Today, 2025, 63:102757. （IF=10.9）
[4] L. Zhang#, J. Wang#, H. Cui, H. Zheng, X. Yin, J. Lin, Y. Wang, Y. Zhao, H. Li g, Q. Chen. Simultaneous knockdown of immune suppressive markers by tumor microenvironment-responsive multifaceted prodrug nanomedicine. ACS Applied Materials & Interfaces, 2023, 15(10), 12864-12881. （IF=8.2）
[5] L. Zhang, H. Zheng, H. Cui, X. et al. Nanomicelle-Based Redox-Responsive Dual-Prodrug for Synergistic Breast Cancer Chemo-Immunotherapy. ACS Applied Nano Materials, 2023, 6, 19, 18263–18274. （IF=5.5）
[6] H. Li#, L. Zhang#, J. Han#, et al. Molecular structural evolution of NIR cationic AIEgens: preclinical antimicrobial pathogens activities and tissues regeneration. CCS Chemistry, 2022, 4, 487-500. （IF=9.2）
[7] L. Zhang, M. Qian, H. Cui, et al. Spatiotemporal concurrent liberation of cytotoxins from dual-prodrug nanomedicine for synergistic antitumor therapy. ACS Applied Materials & Interfaces, 2021.02, 13, 6053–6068. （IF=8.2）
授权专利
[1] ZL202510093662.6，张留伟;陈麒先;张玉峰;林佳奇;崔洪燕，一种逆转肿瘤免疫微环境的多功能纳米制剂及其制备方法和应用
[2] ZL202310403221.2，陈麒先;王静云;崔洪燕;郑浩男;李海东;张留伟 ，一种用于蛋白质递送的多级响应型聚合物囊泡的制备方法
[3] ZL202211567776.2，陈麒先;王静云;郑浩男;崔洪燕;张留伟;李海东，一种能协同化疗逆转肿瘤微环境的JQ1前药纳米粒子及其制备方法和应用
[4] ZL202510139658.9，陈麒先;张宇豪;张留伟，基于变分编码的药物靶标结合性预测方法
[5] ZL202511836248.6，陈麒先;张宇豪;张留伟;崔洪燕，一种基于混合深度学习模型的RNA二级结构预测方法
[6] ZL202111275445.7，王静云;曾爽;陈麒先;张留伟，可激活肿瘤细胞焦亡的细胞器靶向光敏剂及其制备方法和应用
[1] 与北京擎科生物科技股份有限公司研发核酸转染试剂4款，其中小核酸专用转染试剂完成产业化上市
[2] 与上海中翊日化有限公司研发小核酸药物及其递送系统等3款
